Labcorp Acquires BioReference Health Assets for $722M
The purchase adds over 80 patient service centers, consolidating diagnostic infrastructure for healthcare operators.
Updated on Oct. 15, 2026 in Healthcare
Live Poll
Do you believe large laboratory companies acquiring specialized testing operations is good for the healthcare industry?
Labcorp is acquiring BioReference Health assets from Opko Health in a cash deal valued at $722 million. The acquisition, which includes over 80 patient service centers and specialized diagnostic operations, is expected to add $250 million in revenue during its first year.
Why it matters
The deal allows Opko Health to pivot toward its core biopharmaceutical operations while expanding Labcorp's clinical diagnostic footprint. For operators in the healthcare sector, the transaction signals a continued consolidation of patient service infrastructure and diagnostic testing capabilities.
Labcorp is paying $722 million for BioReference Health operations, including over 80 patient service centers, with an additional $150 million possible depending on 4Kscore test performance. The acquired units generated $27.1 million in 2025 revenue and are projected to reach $250 million annually.
The players
Labcorp
A global healthcare diagnostics company providing laboratory testing and drug development services.
Opko Health
A diversified healthcare company focusing on biopharmaceutical development and diagnostic testing.
BioReference Health
A clinical laboratory service provider specializing in diagnostic testing and patient services.
The details
Labcorp gains diagnostic businesses focused on clinical diagnostics, women's health, urology, and corrections. By absorbing these operating assets, Labcorp scales its specialized testing volume and increases its network of patient-facing facilities. Opko Health retains its primary biopharmaceutical business, shifting its resource allocation away from these laboratory services.
Timeline
2025: The 4Kscore prostate cancer test generated $27.1 million in revenue.
October 15, 2026: Labcorp announced the acquisition of BioReference Health assets.
Market Landscape
This acquisition mirrors the broader industry trend of large-scale diagnostic firms consolidating localized patient service infrastructure to achieve operational efficiency. It follows a historical pattern of established labs acquiring specialized testing assets to expand regional reach.
Operators in the diagnostic space should monitor how this transfer of over 80 patient service centers impacts local market pricing and service availability. Financial and procurement managers should evaluate their current lab vendor contracts for potential service level adjustments following the acquisition.
The takeaway
The move underscores the value of specialized diagnostic testing assets in an era of healthcare consolidation. Operators should track how the integration of the 4Kscore test impacts Labcorp's market positioning in the urology and oncology diagnostic segments.
Further reading
For more on industry shifts, see our Healthcare section.
Live Poll
Do you believe large laboratory companies acquiring specialized testing operations is good for the healthcare industry?
